Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟8階 カンファレンス室.

Slides:



Advertisements
Similar presentations
1. 2 Accreditation and Designation of Credit The Network for Continuing Medical Education ( NCME) is accredited by the Accreditation Council for Continuing.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.
4-T Final Three-year Results Slides © University of Oxford Diabetes Trials Unit  4-T slides are copyright and remain the property of the University of.
Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,
Lipid Disorders and Management in Diabetes
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
…in an academic collaboration with ISRCTN
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Role of Rosuvastatin in the Treatment of Dyslipidemia
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
Treating To Target in Type 2 Diabetes 4-T slides are copyright and remain the property of the University of Oxford Diabetes Trials Unit 4-T slides are.
The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,
Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.
INFLAMACION Y ENFERMEDAD CARDIOVASCULAR.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年6月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 12 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年7月 31 日 8:20-8:50 B 棟8階 カンファレンス室.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月 22 日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2009 年 2 月 5 日 8:20-8:50 B 棟8階 カンファレンス室.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
The overwhelming case for LDL-C lowering
A Diabetes Outcome Progression Trial
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年1月 10 日 8:20-8:50 B 棟8階 カンファレンス室.
Diabetes Prevention Program (DPP)
Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride Kann P, Regulski M, Medding J, Ligthelm R A study in people with type.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年9月6日 8:20-8:50 B 棟8階 カンファレンス室.
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月1日 8:20-8:50 B 棟8階 カンファレンス室.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2006 年 12 月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H
Cholesterol Lowering and CV Risk: Meta-analyses
Neal B, et al. Diabetes Care 2015;38:403–411
HDL cholesterol and cardiovascular risk Epidemiological evidence
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
HDL cholesterol and cardiovascular risk
Oxford Niacin Trial.
TNT: Baseline and final LDL cholesterol levels
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report  Scott M. Grundy, Hidenori.
TNT Study: Baseline Characteristics of the Patients
% decrease in LDL-C at 24 weeks from baseline
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,
A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.
Fellström BC, et al. N Engl J Med 2009;360:1455-7
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.
Flow of Patients Through Trial
RECORD Study: Enrollment and Outcomes
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Change in markers of glycometabolism and cardiovascular risk profile.
© The Author(s) Published by Science and Education Publishing.
Presentation transcript:

Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟8階 カンファレンス室

2 Adapted from Rosensen RS. Exp Opin Emerg Drugs 2004;9(2): LaRosa JC et al. N Engl J Med 2005;352: LDL-C achieved mg/dL (mmol/L) WOSCOPS – Placebo AFCAPS - Placebo ASCOT - Placebo AFCAPS - RxWOSCOPS - Rx ASCOT - Rx 4S - Rx HPS - Placebo LIPID - Rx 4S - Placebo CARE - Rx LIPID - Placebo CARE - Placebo HPS - Rx (1.0) 60 (1.6) 80 (2.1) 100 (2.6) 120 (3.1) 140 (3.6) 160 (4.1) 180 (4.7) Event rate (%) 6 Secondary Prevention Primary Prevention Rx - Statin therapy PRA – pravastatin ATV - atorvastatin 200 (5.2) PROVE-IT - PRA PROVE-IT – ATV TNT – ATV10 TNT – ATV80 LDL-C and Cardiovascular Event Rate

Original Article HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events Philip Barter, M.D., Ph.D., Antonio M. Gotto, M.D., D.Phil., John C. LaRosa, M.D., Jaman Maroni, M.D., Michael Szarek, M.S., Scott M. Grundy, M.D., Ph.D., John J.P. Kastelein, M.D., Ph.D., Vera Bittner, M.D., M.S.P.H., Jean-Charles Fruchart, Pharm.D., Ph.D., for the Treating to New Targets Investigators N Engl J Med Volume 357(13): September 27, 2007

Study Overview In a post hoc analysis of the Treating to New Targets study, high-density lipoprotein cholesterol levels in patients receiving statin therapy were shown to be predictive of subsequent major cardiovascular events, even when low- density lipoprotein (LDL) cholesterol levels were taken into account and even among patients with very low levels of LDL cholesterol (<70 mg per deciliter)

Baseline Characteristics of the Patients According to Quintile of HDL Cholesterol Level at Month 3 Barter P et al. N Engl J Med 2007;357:

Multivariate Analysis of the Relationship between HDL Cholesterol Levels at Month 3 and the Risk of Major Cardiovascular Events Barter P et al. N Engl J Med 2007;357:

Multivariate Analysis of the Relationship between Major Cardiovascular Events and Quintiles of HDL Cholesterol Levels Barter P et al. N Engl J Med 2007;357:

Relationship between Major Cardiovascular Events and Ratio of LDL Cholesterol to HDL Cholesterol at Month 3 (Panel A) and Ratio of Total Cholesterol to HDL Cholesterol at Month 3 (Panel B) Barter P et al. N Engl J Med 2007;357:

Relationship between HDL Cholesterol Levels and the Risk of Major Cardiovascular Events Barter P et al. N Engl J Med 2007;357:

Conclusion In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter

Original Article Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes Rury R. Holman, M.B., Ch.B., F.R.C.P., Kerensa I. Thorne, M.Sc., Andrew J. Farmer, D.M., F.R.C.G.P., Melanie J. Davies, M.D., F.R.C.P., Joanne F. Keenan, B.A., Sanjoy Paul, Ph.D., Jonathan C. Levy, M.D., F.R.C.P., for the 4-T Study Group N Engl J Med Volume 357(17): October 25, 2007

Study Overview In an open-label trial, patients with type 2 diabetes with a suboptimal glycated hemoglobin level while receiving a maximally tolerated dose of metformin and sulfonylurea were randomly assigned to receive biphasic, prandial, or basal insulin The addition of a single analogue-insulin formulation resulted in a glycated hemoglobin level of 6.5% or less in a minority of patients at 1 year. Regimens of biphasic or prandial insulin had greater efficacy than did the basal regimen but were associated with greater risks of hypoglycemia and weight gain

Enrollment and Outcomes Holman RR et al. N Engl J Med 2007;357:

Characteristics of the Patients at Baseline Holman RR et al. N Engl J Med 2007;357:

Primary and Secondary Outcomes at 1 Year Holman RR et al. N Engl J Med 2007;357:

Outcomes and Changes from Baseline at 1 Year Holman RR et al. N Engl J Med 2007;357:

Mean (±SE) Percentage Change from Baseline to 1 Year in Glycated Hemoglobin, Fasting Plasma Glucose, Postprandial Glucose, and Body Weight (Panel A) and Mean (+SD) Hypoglycemic-Event Rate (Panel B) Holman RR et al. N Engl J Med 2007;357:

Adverse Events Holman RR et al. N Engl J Med 2007;357:

Conclusion A single analogue-insulin formulation added to metformin and sulfonylurea resulted in a glycated hemoglobin level of 6.5% or less in a minority of patients at 1 year. The addition of biphasic or prandial insulin aspart reduced levels more than the addition of basal insulin detemir but was associated with greater risks of hypoglycemia and weight gain